Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32837747
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Clinical Characteristics and Outcomes of Type 2 Diabetes Patients Infected with
COVID-19: A Retrospective Study
#MMPMID32837747
Chen Y
; Chen J
; Gong X
; Rong X
; Ye D
; Jin Y
; Zhang Z
; Li J
; Guo J
Engineering (Beijing)
2020[Oct]; 6
(10
): 1170-1177
PMID32837747
show ga
Diabetes and its related metabolic disorders have been reported as the leading
comorbidities in patients with coronavirus disease 2019 (COVID-19). This clinical
study aims to investigate the clinical features, radiographic and laboratory
tests, complications, treatments, and clinical outcomes in COVID-19 patients with
or without diabetes. This retrospective study included 208 hospitalized patients
(? 45 years old) with laboratory-confirmed COVID-19 during the period between 12
January and 25 March 2020. Information from the medical record, including
clinical features, radiographic and laboratory tests, complications, treatments,
and clinical outcomes, were extracted for the analysis. 96 (46.2%) patients had
comorbidity with type 2 diabetes. In COVID-19 patients with type 2 diabetes, the
coexistence of hypertension (58.3% vs 31.2%), coronary heart disease (17.1% vs
8.0%), and chronic kidney diseases (6.2% vs 0%) was significantly higher than in
COVID-19 patients without type 2 diabetes. The frequency and degree of
abnormalities in computed tomography (CT) chest scans in COVID-19 patients with
type 2 diabetes were markedly increased, including ground-glass opacity (85.6% vs
64.9%, P < 0.001) and bilateral patchy shadowing (76.7% vs 37.8%, P < 0.001). In
addition, the levels of blood glucose (7.23 mmol·L(-1) (interquartile range
(IQR): 5.80-9.29) vs 5.46 mmol·L(-1) (IQR: 5.00-6.46)), blood low-density
lipoprotein cholesterol (LDL-C) (2.21 mmol·L(-1) (IQR: 1.67-2.76) vs
1.75 mmol·L(-1) (IQR: 1.27-2.01)), and systolic pressure (130 mmHg (IQR: 120-142)
vs 122 mmHg (IQR: 110-137)) (1 mmHg = 133.3 Pa) in COVID-19 patients with
diabetes were significantly higher than in patients without diabetes (P < 0.001).
The coexistence of type 2 diabetes and other metabolic disorders is common in
patients with COVID-19, which may potentiate the morbidity and aggravate COVID-19
progression. Optimal management of the metabolic hemostasis of glucose and lipids
is the key to ensuring better clinical outcomes. Increased clinical vigilance is
warranted for COVID-19 patients with diabetes and other metabolic diseases that
are fundamental and chronic conditions.
free
free
free
